ABCL (AbCellera Biologics) Tariff Resilience Score: 7/10 (As of Jun. 27, 2026)


ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $7.38
GF Value $5.62
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics Tariff Resilience Score?

AbCellera Biologics ABCL +10.81% 59 Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,378 Biotechnology companies, AbCellera Biologics ranks better than 90.42% on this metric.

AbCellera Biologics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

AbCellera Biologics has AbCellera's focus on biotechnology and partnerships with global pharmaceutical companies provide some insulation from tariffs. The industry often benefits from exemptions, and its innovative capabilities offer pricing power to mitigate potential impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AbCellera Biologics might have Highly Resilient.

AbCellera Biologics  (NAS:ABCL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AbCellera Biologics Tariff Resilience Score Related Terms

ABCL vs SRPT, RAPP, RXRX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, AbCellera Biologics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Tariff Resilience Score falls into.


ABCL
59GF Score
AbCellera Biologics Inc ABCL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
AbCellera Biologics (ABCL) has a Tariff Resilience Score of 7 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AbCellera Biologics ranks #132 out of 1378 companies in the Biotechnology industry, placing it in the top 9.6%.
Is AbCellera Biologics' Tariff Resilience Score too high?
AbCellera Biologics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. AbCellera Biologics' value of 7 is 75% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #132 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Tariff Resilience Score compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #132 out of 1378 companies for Tariff Resilience Score. This places AbCellera Biologics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. AbCellera Biologics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Tariff Resilience Score: 7
  • GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
  • GF Score™: 59/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1378)

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.38
Price
$5.62
GF Value